Severe myoclonic epilepsy in infancy: toward an optimal treatment.
about
StiripentolReduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancyComprehensive care of children with Dravet syndromeClinical review of genetic epileptic encephalopathiesPrevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort studyFine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-SeqIncidence of Dravet Syndrome in a US Population.Vagus nerve stimulation for genetic epilepsy with febrile seizures plus (GEFS+) accompanying seizures with impaired consciousnessEpileptic encephalopathies in adults and childhood.Stiripentol.Temperature-dependent changes in neuronal dynamics in a patient with an SCN1A mutation and hyperthermia induced seizuresAdults with a history of possible Dravet syndrome: an illustration of the importance of analysis of the SCN1A gene.Overall management of patients with Dravet syndrome."Epileptic encephalopathy" of infancy and childhood: electro-clinical pictures and recent understandingsStiripentol and vigabatrin current roles in the treatment of epilepsy.Vagus Nerve Stimulation in Intractable Epilepsy Associated With SCN1A Gene Abnormalities.Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome.Therapy for hyperthermia-induced seizures in Scn1a mutant rats.Scn1a dysfunction alters behavior but not the effect of stress on seizure response.Successful use of fenfluramine as an add-on treatment for Dravet syndrome.
P2860
Q28261980-A586120B-2C3F-4E70-AFBF-E5CEAEC22C34Q28585126-78DE9FE1-6E8D-408B-8729-A045F137D052Q29030607-7079C200-568F-43BC-BD26-F81FA532FD7CQ30537230-681773C2-4E3B-48D4-B61C-7B4DF89C0E2FQ34770167-B2915CC9-B102-45D6-B02E-73AB87053B7BQ36170695-A5D4D2F6-6889-444F-B91A-4713AF539905Q36210601-CDD83A50-B155-46FA-883A-6634A40CD504Q36245140-04518CD4-55BA-4323-A349-1641F8C093EDQ36302381-24D43DD0-1A52-4E07-93BE-291E04042254Q36697489-9910F7DA-D906-4C96-85FB-1B13A948BAE2Q37223382-27421434-B411-4D93-813A-6D9ADE5283ACQ37849322-B16266D9-E5D4-4FCF-9884-25D0C18E948FQ37866833-AFF6546C-BD71-45DF-90E3-37223FB63CACQ37883054-93C38364-152F-4753-ACFA-B9E03D12D24AQ38757727-907C2CFA-6477-4341-AEDC-87F42E9AB736Q39082444-4F9B76A0-660D-4068-90FA-6CA712BD8D21Q39598983-7EFADB6F-6E4C-41B0-902E-F4E15C40E369Q40328281-D2E558DB-89DD-4C10-94C1-3A6E734D36BFQ47605720-D873EFAB-427B-4F32-8CDB-FE6EE07AAD44Q51342135-9412D971-7F1E-45AA-91D1-DD62A7F1F88E
P2860
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
@en
type
label
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
@en
prefLabel
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
@en
P2093
P2860
P1476
Severe myoclonic epilepsy in infancy: toward an optimal treatment.
@en
P2093
Berten Ceulemans
Herman Willekens
Lieve Claes
Lieven Lagae
Paul Thiry
P2860
P304
P356
10.1177/08830738040190070701
P577
2004-07-01T00:00:00Z